Major depression (MDE) has metabolic and neuroendocrine correlates, which point to a biological overlap between MDE and cardiovascular diseases. Whereas the hypothalamic-pituitary-adrenocortical axis has long been recognized for its involvement in depression, the focus was mostly on cortisol/corticosterone, whereas aldosterone appears to be the ‘forgotten' stress hormone. Part of the reason for this is that the receptors for aldosterone, the mineralocorticoid receptors (MR), were thought to be occupied by glucocorticoids in most parts of the brain. However, recently it turned out that aldosterone acts selectively in relevant mood-regulating brain areas, without competing with cortisol/corticosterone. These areas include the nucleus of the solitary tract (NTS), the amygdala and the paraventricular nucleus of the hypothalamus. These regions are intimately involved in the close relationship between emotional and vegetative symptoms. Genetic analysis supports the role of aldosterone and of MR-related pathways in the pathophysiology of depression. Functional markers for these pathways in animal models as well as in humans are available and allow an indirect assessment of NTS function. They include heart rate variability, baroreceptor reflex sensitivity, blood pressure, salt taste sensitivity and slow-wave sleep. MR activation in the periphery is related to electrolyte regulation. MR overactivity is a risk factor for diabetes mellitus and a trigger of inflammatory processes. These markers can be used not only to assist the development of new treatment compounds, but also for a personalized approach to treat patients with depression and related disorders by individual dose titration with an active medication, which targets this system.

Keywords:
Aldosterone, Endothelin, 5-HT3 receptor, 5-HT7 receptor, FKBP5, NMDA, Mineralocorticoid receptor, Nucleus of the solitary tract, Oxytocin, Therapy-refractory major depression
1.
Almeida OP, Flicker L, Norman P, Hankey GJ, Vasikaran S, van Bockxmeer FM, Jamrozik K: Association of cardiovascular risk factors and disease with depression in later life. Am J Geriatr Psychiatry 2007;15:506-513.
2.
Nemeroff CB, Goldschmidt-Clermont PJ: Heartache and heartbreak - the link between depression and cardiovascular disease. Nat Rev Cardiol 2012;9:526-539.
3.
Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N: Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med 2013;11:129.
4.
Selye H: Stress and disease. Laryngoscope 1955;65:500-514.
5.
Chen H, Sun F, Zhong X, Shao Y, Yoshimura A, Liu Y: Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. Kidney Blood Press Res 2013;37:557-566.
6.
Namsolleck P, Unger T: Aldosterone synthase inhibitors in cardiovascular and renal diseases. Nephrol Dial Transplant 2014;29(suppl 1):i62-i68.
7.
Whitworth JA, Williamson PM, Mangos G, Kelly JJ: Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag 2005;1:291-299.
8.
Abraham SB, Rubino D, Sinaii N, Ramsey S, Nieman LK: Cortisol, obesity, and the metabolic syndrome: a cross-sectional study of obese subjects and review of the literature. Obesity (Silver Spring) 2013;21:E105-E117.
9.
Murck H, Schussler P, Steiger A: Renin-angiotensin-aldosterone system: the forgotten stress hormone system: relationship to depression and sleep. Pharmacopsychiatry 2012;45:83-95.
10.
Gomez-Sanchez EP: Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule? Trends Endocrinol Metab 2011;22:179-187.
11.
De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M: Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998;19:269-301.
12.
Van Acker SA, Fluttert MF, Sibug RM, De Kloet ER: Intracerebroventricular administration of a glucocorticoid receptor antagonist enhances the cardiovascular responses to brief restraint stress. Eur J Pharmacol 2001;430:87-91.
13.
Brady LS, Whitfield HJ Jr, Fox RJ, Gold PW, Herkenham M: Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 1991;87:831-837.
14.
Lopez JF, Chalmers DT, Little KY, Watson SJ: A.E. Bennett Research Award. Regulation of serotonin-1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 1998;43:547-573.
15.
Konrad C, Ukas T, Nebel C, Arolt V, Toga AW, Narr KL: Defining the human hippocampus in cerebral magnetic resonance images - an overview of current segmentation protocols. Neuroimage 2009;47:1185-1195.
16.
De Kloet ER, Van Acker SA, Sibug RM, Oitzl MS, Meijer OC, Rahmouni K, de Jong W: Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int 2000;57:1329-1336.
17.
Rahmouni K, Sibug RM, De Kloet ER, Barthelmebs M, Grima M, Imbs JL, De Jong W: Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension. Eur J Pharmacol 2002;436:207-216.
18.
Geerling JC, Kawata M, Loewy AD: Aldosterone-sensitive neurons in the rat central nervous system. J Comp Neurol 2006;494:515-527.
19.
Geerling JC, Loewy AD: Aldosterone in the brain. Am J Physiol Renal Physiol 2009;297:F559-F576.
20.
Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23:477-501.
21.
Gold PW, Chrousos GP: Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002;7:254-275.
22.
Nemeroff CB, Mayberg HS, Krahl SE, McNamara J, Frazer A, Henry TR, George MS, Charney DS, Brannan SK: VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology 2006;31:1345-1355.
23.
Franklin M, Bermudez I, Hlavacova N, Babic S, Murck H, Schmuckermair C, Singewald N, Gaburro S, Jezova D: Aldosterone increases earlier than corticosterone in new animal models of depression: is this an early marker? J Psychiatr Res 2012;46:1394-1397.
24.
Hlavacova N, Wes PD, Ondrejcakova M, Flynn ME, Poundstone PK, Babic S, Murck H, Jezova D: Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int J Neuropsychopharmacol 2012;15:247-265.
25.
Opstad PK, Oktedalen O, Aakvaag A, Fonnum F, Lund PK: Plasma renin activity and serum aldosterone during prolonged physical strain. The significance of sleep and energy deprivation. Eur J Appl Physiol Occup Physiol 1985;54:1-6.
26.
Hullin RP, Jerram TC, Lee MR, Levell MJ, Tyrer SP: Renin and aldosterone relationships in manic depressive psychosis. Br J Psychiatry 1977;131:575-581.
27.
Holsboer F, Dorr HG, Sippell WG: Blunted aldosterone response to dexamethasone in female patients with endogenous depression. Psychoneuroendocrinology 1982;7:155-162.
28.
Murck H, Held K, Ziegenbein M, Kunzel H, Koch K, Steiger A: The renin-angiotensin-aldosterone system in patients with depression compared to controls - a sleep endocrine study. BMC Psychiatry 2003;3:15.
29.
Emanuele E, Geroldi D, Minoretti P, Coen E, Politi P: Increased plasma aldosterone in patients with clinical depression. Arch Med Res 2005;36:544-548.
30.
Hallberg L, Westrin A, Isaksson A, Janelidze S, Traskman-Bendz L, Brundin L: Decreased aldosterone in the plasma of suicide attempters with major depressive disorder. Psychiatry Res 2011;187:135-139.
31.
Häfner S, Baumert J, Emeny RT, Lacruz ME, Bidlingmaier M, Reincke M, Kuenzel H, Holle R, Rupprecht R, Ladwig KH: To live alone and to be depressed, an alarming combination for the renin-angiotensin-aldosterone-system (RAAS). Psychoneuroendocrinology 2012;37:230-237.
32.
Häfner S, Baumert J, Emeny RT, Lacruz ME, Bidlingmaier M, Reincke M, Ladwig KH: Hypertension and depressed symptomatology: a cluster related to the activation of the renin-angiotensin-aldosterone system (RAAS). Findings from population based KORA F4 study. Psychoneuroendocrinology 2013;38:2065-2074.
33.
Sonino N, Fallo F, Fava GA: Psychological aspects of primary aldosteronism. Psychother Psychosom 2006;75:327-330.
34.
Apostolopoulou K, Kunzel HE, Gerum S, Merkle K, Schulz S, Fischer E, Pallauf A, Brand V, Bidlingmaier M, Endres S, Beuschlein F, Reincke M: Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: a cross-sectional study. World J Biol Psychiatry 2014;15:26-35.
35.
Kunzel HE: Psychopathological symptoms in patients with primary hyperaldosteronism - possible pathways. Horm Metab Res 2012;44:202-207.
36.
Steiger A, Murck H: REM sleep in patients with depression; in Mallick BN, et al (eds): Rapid Eye Movement Sleep. Cambridge, Cambridge University Press, 2011, pp 383-394.
37.
Ising M, Kunzel HE, Binder EB, Nickel T, Modell S, Holsboer F: The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1085-1093.
38.
Wu TC, Chen HT, Chang HY, Yang CY, Hsiao MC, Cheng ML, Chen JC: Mineralocorticoid receptor antagonist spironolactone prevents chronic corticosterone induced depression-like behavior. Psychoneuroendocrinology 2013;38:871-883.
39.
Wenzl H, Garbe A, Nowak H: Distribution of 9-fluorhydrocortisone in the animal organism (in German). Arzneimittelforschung 1971;21(suppl):1123-1126.
40.
Otte C, Yassouridis A, Jahn H, Maass P, Stober N, Wiedemann K, Kellner M: Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci 2003;58:B900-B905.
41.
Otte C, Hinkelmann K, Moritz S, Yassouridis A, Jahn H, Wiedemann K, Kellner M: Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res 2010;44:339-346.
42.
Khalid BA, Lim AT, Fraillon DR, Funder JW: Mineralocorticoid and glucocorticoid effects on 31,000- and 29,000-dalton proopiomelanocortin in rat anterior pituitary and neurointermediate lobe. J Clin Invest 1982;70:443-452.
43.
Karamouzis I, Berardelli R, Marinazzo E, D'Angelo V, Zinna D, Minetto MA, Zichi C, Fussotto B, Giordano R, Ghigo E, Arvat E: The acute effect of fludrocortisone on basal and hCRH-stimulated hypothalamic-pituitary-adrenal (HPA) axis in humans. Pituitary 2013;16:378-385.
44.
Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H: Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry 2003;60:24-28.
45.
Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ: The role of mineralocorticoid receptor function in treatment-resistant depression. J Psychopharmacol 2013;27:1169-1179.
46.
Buettner M, Jezova D, Konrad C, Kircher T, Murck H: Central and peripheral mineralocorticoid receptor function and its impact on the course of depression. Biol Psychiatry 2014; 75:114S.
47.
Ripke S, Wray NR, Lewis CM, et al: A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 2013;18:497-511.
48.
Ising M, Holsboer F: Genetics of stress response and stress-related disorders. Dialogues Clin Neurosci 2006;8:433-444.
49.
Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T: Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol 2010;61:509-521.
50.
Baghai TC, Schule C, Zwanzger P, Minov C, Schwarz MJ, de Jonge S, Rupprecht R, Bondy B: Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol Psychiatry 2001;6:258-259.
51.
Baghai TC, Schule C, Zill P, Deiml T, Eser D, Zwanzger P, Ella R, Rupprecht R, Bondy B: The angiotensin I-converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men. Neurosci Lett 2004;363:38-42.
52.
Baghai TC, Binder EB, Schule C, Salyakina D, Eser D, Lucae S, Zwanzger P, Haberger C, Zill P, Ising M, Deiml T, Uhr M, Illig T, Wichmann HE, Modell S, Nothdurfter C, Holsboer F, Muller-Myhsok B, Moller HJ, Rupprecht R, Bondy B: Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry 2006;11:1003-1015.
53.
Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, Papiol S, Seaman S, Lucae S, Kohli MA, Nickel T, Kunzel HE, Fuchs B, Majer M, Pfennig A, Kern N, Brunner J, Modell S, Baghai T, Deiml T, Zill P, Bondy B, Rupprecht R, Messer T, Kohnlein O, Dabitz H, Bruckl T, Muller N, Pfister H, Lieb R, Mueller JC, Lohmussaar E, Strom TM, Bettecken T, Meitinger T, Uhr M, Rein T, Holsboer F, Muller-Myhsok B: Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004;36:1319-1325.
54.
Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, Muller-Myhsok B, Holsboer F, Binder EB: Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010;35:727-740.
55.
Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS: 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 2001;21:3572-3579.
56.
Klengel T, Heck A, Pfister H, Bruckl T, Hennings JM, Menke A, Czamara D, Muller-Myhsok B, Ising M: Somatization in major depression - clinical features and genetic associations. Acta Psychiatr Scand 2011;124:317-328.
57.
Jaaskelainen T, Makkonen H, Palvimo JJ: Steroid up-regulation of FKBP51 and its role in hormone signaling. Curr Opin Pharmacol 2011;11:326-331.
58.
Nagase M, Fujita T: Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol 2013;9:86-98.
59.
Petrovich E, Asher C, Garty H: Induction of FKBP51 by aldosterone in intestinal epithelium. J Steroid Biochem Mol Biol 2014;139:78-87.
60.
Keck ME, Kern N, Erhardt A, Unschuld PG, Ising M, Salyakina D, Muller MB, Knorr CC, Lieb R, Hohoff C, Krakowitzky P, Maier W, Bandelow B, Fritze J, Deckert J, Holsboer F, Muller-Myhsok B, Binder EB: Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1196-1204.
61.
Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Muller-Myhsok B: A genome-wide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009;66:966-975.
62.
Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B, Holsboer F: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008;57:203-209.
63.
Uhr M, Holsboer F, Muller MB: Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both Mdr1a and Mdr1b P-glycoproteins. J Neuroendocrinol 2002;14:753-759.
64.
Muller MB, Keck ME, Binder EB, Kresse AE, Hagemeyer TP, Landgraf R, Holsboer F, Uhr M: ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: implications for affective disorder. Neuropsychopharmacology 2003;28:1991-1999.
65.
Bello-Reuss E, Ernest S, Holland OB, Hellmich MR: Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am J Physiol Cell Physiol 2000;278:1256-1265.
66.
Parker RB, Yates CR, Laizure SC, Weber KT: P-glycoprotein modulates aldosterone plasma disposition and tissue uptake. J Cardiovasc Pharmacol 2006;47:55-59.
67.
Brem AS, Morris DJ, Gong R: Aldosterone-induced fibrosis in the kidney: questions and controversies. Am J Kidney Dis 2011;58:471-479.
68.
Tonge DA, de Burgh HT, Docherty R, Humphries MJ, Craig SE, Pizzey J: Fibronectin supports neurite outgrowth and axonal regeneration of adult brain neurons in vitro. Brain Res 2012;1453:8-16.
69.
Dyment DA, Smith AC, Alcantara D, Schwartzentruber JA, Basel-Vanagaite L, Curry CJ, Temple IK, Reardon W, Mansour S, Haq MR, Gilbert R, Lehmann OJ, Vanstone MR, Beaulieu CL, Majewski J, Bulman DE, O'Driscoll M, Boycott KM, Innes AM: Mutations in PIK3R1 cause SHORT syndrome. Am J Hum Genet 2013;93:158-166.
70.
Duman RS, Li N, Liu RJ, Duric V, Aghajanian G: Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012;62:35-41.
71.
Zarate C, Duman RS, Liu G, Sartori S, Quiroz J, Murck H: New paradigms for treatment-resistant depression. Ann NY Acad Sci 2013;1292:21-31.
72.
Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, Kahn CR: Reduced expression of the murine p85α subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 2002;109:141-149.
73.
Kohan DE, Rossi NF, Inscho EW, Pollock DM: Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011;91:1-77.
74.
Di Filippo C, D'Amico M, Piegari E, Rinaldi B, Filippelli A, Rossi F: Local administration of ETA (but not ETB) blockers into the PAG area of the brain decreases blood pressure of DOCA-salt rats. Naunyn Schmiedebergs Arch Pharmacol 2002;366:123-126.
75.
Bauer B, Hartz AM, Miller DS: Tumor necrosis factor α and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 2007;71:667-675.
76.
Joels M, Sarabdjitsingh RA, Karst H: Unraveling the time domains of corticosteroid hormone influences on brain activity: rapid, slow, and chronic modes. Pharmacol Rev 2012;64:901-938.
77.
Karst H, Berger S, Turiault M, Tronche F, Schutz G, Joels M: Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc Natl Acad Sci USA 2005;102:19204-19207.
78.
Kellner M, Peiter A, Häfner M, Feuring M, Christ M, Wehling M, Falkenstein E, Losel R: Early aldosterone up-regulated genes: new pathways for renal disease? Kidney Int 2003;64:1199-1207.
79.
Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V: (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev 2006;86:1151-1178.
80.
Yuen EY, Liu W, Karatsoreos IN, Ren Y, Feng J, McEwen BS, Yan Z: Mechanisms for acute stress-induced enhancement of glutamatergic transmission and working memory. Mol Psychiatry 2011;16:156-170.
81.
Frodl T, Carballedo A, Hughes MM, Saleh K, Fagan A, Skokauskas N, McLoughlin DM, Meaney J, O'Keane V, Connor TJ: Reduced expression of glucocorticoid-inducible genes GILZ and Sgk-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl Psychiatry 2012;2:e88.
82.
Singewald N, Sharp T: Neuroanatomical targets of anxiogenic drugs in the hindbrain as revealed by Fos immunocytochemistry. Neuroscience 2000;98:759-770.
83.
Flak JN, Solomon MB, Jankord R, Krause EG, Herman JP: Identification of chronic stress-activated regions reveals a potential recruited circuit in rat brain. Eur J Neurosci 32012;6:2547-2555.
84.
Damasio A, Carvalho GB: The nature of feelings: evolutionary and neurobiological origins. Nat Rev Neurosci 2013;14:143-152.
85.
Craig AD: How do you feel? Interoception: the sense of the physiological condition of the body. Nat Rev Neurosci 2002;3:655-666.
86.
Wang M, Hammarback S, Lindhe BA, Backstrom T: Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995;74:803-808.
87.
Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A: Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501.
88.
Wingenfeld K, Kuehl LK, Janke K, Hinkelmann K, Dziobek I, Fleischer J, Otte C, Roepke S: Enhanced emotional empathy after mineralocorticoid receptor stimulation in women with borderline personality disorder and healthy women. Neuropsychopharmacology 2014;39:1799-1804.
89.
Hlavacova N, Bakos J, Jezova D: Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release. J Psychopharmacol 2010;24:779-786.
90.
Murck H: Atypical depression spectrum disorder - neurobiology and treatment. Acta Neuropsychiatr 2003;15:227-241.
91.
Bou-Holaigah I, Rowe PC, Kan J, Calkins H: The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995;274:961-967.
92.
Souza RR, Dal Bo S, de Kloet ER, Oitzl MS, Carobrez AP: Paradoxical mineralocorticoid receptor-mediated effect in fear memory encoding and expression of rats submitted to an olfactory fear conditioning task. Neuropharmacology 2013;79C:201-211.
93.
Mork A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sanchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensbol TB: Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012;340:666-675.
94.
Lawrence AJ, Jarrott B: Neurochemical modulation of cardiovascular control in the nucleus tractus solitarius. Prog Neurobiol 1996;48:21-53.
95.
Chianca DA Jr, Machado BH: Microinjection of NMDA antagonist into the NTS of conscious rats blocks the Bezold-Jarisch reflex. Brain Res 1996;718:185-188.
96.
Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-864.
97.
Murck H: Ketamine, magnesium and major depression - from pharmacology to pathophysiology and back. J Psychiatr Res 2013;47:955-965.
98.
Andresen MC, Fawley JA, Hofmann ME: Peptide and lipid modulation of glutamatergic afferent synaptic transmission in the solitary tract nucleus. Front Neurosci 2012;6:191.
99.
Bar KJ, Boettger MK, Berger S, Baier V, Sauer H, Yeragani VK, Voss A: Decreased baroreflex sensitivity in acute schizophrenia. J Appl Physiol 1985;102:1051-1056.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.